NEW YORK, Sept 10 – Atugen, a Berlin-based functional genomics company, said Monday that Arena Pharmaceuticals had agreed to evaluate its G-protein coupled receptor technology.

Under the terms of the deal, Atugen’s US-based subsidiary will receive central nervous system gene targets from Arena for evaluation using its GeneBlocs gene expression technologies. The company will then try to determine gene function in vivo.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.